Latest News:     Don’t forget to renew your membership now for 2013. Prices go up November 1st, 2012

          1.  Aclasta now available for osteoporosis with limited use code 436.

For the treatment of osteoporosis in postmenopausal women who
would otherwise be eligible for funding for oral bisphosphonates,
but for whom bisphosphonates are contraindicated due to
abnormalities of the esophagus (e.g., esophageal stricture or
achalasia), and have at least two of the following:
– Age greater than 75 years old
– A prior fragility fracture
– A bone mineral density (BMD) T-score less than or equal to -2.5

      2. Abatacept (Orencia) now available through EAP for polyarticular JIA, see criteria here.

      3. Pharmacists now have ability to switch between methotrexate subcutaneously and by mouth, with understanding that physician must be notified.

      4. Canadian government has sent a warning re intereaction between Methotrexate and PPIs which can be seen here.

      5. EAP now accepting requests for OxyNeo which will be required by next March, so send them in now to avoid the rush next spring. The new form is here.

      6. Here is an infobulletin on the Provincial Low-Back Pain Strategy.

      7.  Here is an Infobulletin on the new Medical Claims Electronic Data Transfer web page.